4E-BP restrains eIF4E phosphorylation

References

• Sonenberg N, Morgan MA, Merrick WC, Shatkin AJ. A polypeptide in eukaryotic initiation factors that crosslinks specifically to the 5′-terminal cap in mRNA. Proc Natl Acad Sci U S A 1978; 75:4843 - 7; http://dx.doi.org/10.1073/pnas.75.10.4843; PMID: 217002
   PubMed Web of Science ®Google Scholar
• von der Haar T, Gross JD, Wagner G, McCarthy JE. The mRNA cap-binding protein eIF4E in post-transcriptional gene expression. Nat Struct Mol Biol 2004; 11:503 - 11; http://dx.doi.org/10.1038/nsmb779; PMID: 15164008
   PubMed Web of Science ®Google Scholar
• Martineau Y, Azar R, Bousquet C, Pyronnet S. Anti-oncogenic potential of the eIF4E-binding proteins. Oncogene 2013; 32:671 - 7; http://dx.doi.org/10.1038/onc.2012.116; PMID: 22508483
   PubMed Web of Science ®Google Scholar
• Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 1990; 345:544 - 7; http://dx.doi.org/10.1038/345544a0; PMID: 2348862
   PubMed Web of Science ®Google Scholar
• Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007; 21:3232 - 7; http://dx.doi.org/10.1101/gad.1604407; PMID: 18055695
   PubMed Web of Science ®Google Scholar
• Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A 2010; 107:14134 - 9; http://dx.doi.org/10.1073/pnas.1005320107; PMID: 20679199
   PubMed Web of Science ®Google Scholar
• Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 1997; 16:1909 - 20; http://dx.doi.org/10.1093/emboj/16.8.1909; PMID: 9155017
   PubMed Web of Science ®Google Scholar
• Ueda T, Sasaki M, Elia AJ, Chio II, Hamada K, Fukunaga R, et al. Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci U S A 2010; 107:13984 - 90; http://dx.doi.org/10.1073/pnas.1008136107; PMID: 20679220
   PubMed Web of Science ®Google Scholar
• Pyronnet S. Phosphorylation of the cap-binding protein eIF4E by the MAPK-activated protein kinase Mnk1. Biochem Pharmacol 2000; 60:1237 - 43; http://dx.doi.org/10.1016/S0006-2952(00)00429-9; PMID: 11007962
   PubMed Web of Science ®Google Scholar
• Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter T, Sonenberg N. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J 1999; 18:270 - 9; http://dx.doi.org/10.1093/emboj/18.1.270; PMID: 9878069
   PubMed Web of Science ®Google Scholar
• Mader S, Lee H, Pause A, Sonenberg N. The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF-4 gamma and the translational repressors 4E-binding proteins. Mol Cell Biol 1995; 15:4990 - 7; PMID: 7651417
   PubMed Web of Science ®Google Scholar
• Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010; 17:249 - 61; http://dx.doi.org/10.1016/j.ccr.2010.01.021; PMID: 20227039
   PubMed Web of Science ®Google Scholar
• She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010; 18:39 - 51; http://dx.doi.org/10.1016/j.ccr.2010.05.023; PMID: 20609351
   PubMed Web of Science ®Google Scholar
• Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, Lawrence JC, Jr., Abraham RT. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science (New York, NY 1997; 277:99-101.
   Google Scholar
• Svitkin YV, Gradi A, Imataka H, Morino S, Sonenberg N. Eukaryotic initiation factor 4GII (eIF4GII), but not eIF4GI, cleavage correlates with inhibition of host cell protein synthesis after human rhinovirus infection. J Virol 1999; 73:3467 - 72; PMID: 10074204
   PubMed Web of Science ®Google Scholar
• Hou J, Lam F, Proud C, Wang S. Targeting Mnks for cancer therapy. Oncotarget 2012; 3:118 - 31; PMID: 22392765
   PubMed Web of Science ®Google Scholar
• Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 2004; 24:6539 - 49; http://dx.doi.org/10.1128/MCB.24.15.6539-6549.2004; PMID: 15254222
   PubMed Web of Science ®Google Scholar
• Martineau Y, Azar R, Müller D, Lasfargues C, El Khawand S, Anesia R, et al. Pancreatic tumours escape from translational control through 4E-BP1 loss. Oncogene 2013; http://dx.doi.org/10.1038/onc.2013.100; PMID: 23563181
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj A, Liu Y, Kozma SC, Thomas G, Sonenberg N. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science (New York, NY 2010; 328:1172-6.
   Google Scholar